These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21937869)

  • 41. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson's disease.
    Katz KA; Cotsarelis G; Gupta R; Seykora JT
    J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S103-4. PubMed ID: 17052518
    [No Abstract]   [Full Text] [Related]  

  • 42. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.
    Grosset KA; Grosset DG
    Mov Disord; 2005 May; 20(5):616-9. PubMed ID: 15719417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dilemma in Parkinson's Treatment; Levodopa Monotherapy May be the Best Choice.
    Abbasi MH; Esmaeili S; Habibi SA; Shahidi GA
    J Clin Neurosci; 2020 Sep; 79():219-223. PubMed ID: 33070900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pramipexole reduces the prevalence of fatigue in patients with Parkinson's disease.
    Morita A; Okuma Y; Kamei S; Yoshii F; Yamamoto T; Hashimoto S; Utsumi H; Hatano T; Hattori N; Matsumura M; Takahashi K; Nogawa S; Watanabe Y; Miyamoto T; Miyamoto M; Hirata K
    Intern Med; 2011; 50(19):2163-8. PubMed ID: 21963735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Depressive symptoms and motor condition in Parkinson's disease patients].
    Stella F; Bucken-Gobbi LT; Gobbi S; Sant'Ana-Simões C
    Rev Neurol; 2007 Nov 16-30; 45(10):594-8. PubMed ID: 18008264
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidemiology of major depression in Belgian parkinsonian patients.
    Vanderheyden JE; Gonce M; Bourgeois P; Cras P; De Nayer AR; Flamez A; Supiot F; Donneau AF; Albert A; Berlaimont V;
    Acta Neurol Belg; 2010 Jun; 110(2):148-56. PubMed ID: 20873444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of pramipexole dose-response relationships in Parkinson's disease.
    Wang Y; Sun SG; Zhu SQ; Liu CF; Liu YM; Di Q; Shang HF; Ren Y; Xiang W; Chen SD
    Drug Des Devel Ther; 2017; 11():83-89. PubMed ID: 28096656
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
    Schapira AH; McDermott MP; Barone P; Comella CL; Albrecht S; Hsu HH; Massey DH; Mizuno Y; Poewe W; Rascol O; Marek K
    Lancet Neurol; 2013 Aug; 12(8):747-55. PubMed ID: 23726851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone?
    Fernandez HH; Merello M
    Lancet Neurol; 2010 Jun; 9(6):556-7. PubMed ID: 20452824
    [No Abstract]   [Full Text] [Related]  

  • 53. Role of pramipexole in the management of Parkinson's disease.
    Antonini A; Barone P; Ceravolo R; Fabbrini G; Tinazzi M; Abbruzzese G
    CNS Drugs; 2010 Oct; 24(10):829-41. PubMed ID: 20839895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.
    Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Salin L; Juhel N; Poewe W;
    Neurology; 2011 Aug; 77(8):767-74. PubMed ID: 21832216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Depressive symptoms in Parkinson's disease.
    Lemke MR
    Eur J Neurol; 2008 Apr; 15 Suppl 1():21-5. PubMed ID: 18353133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Mirapex (pramipexole) in the treatment of non-motor disturbances in Parkinson's disease].
    Nodel' MR; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(5):32-8. PubMed ID: 18577955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.
    Shannon KM; Bennett JP; Friedman JH
    Neurology; 1997 Sep; 49(3):724-8. PubMed ID: 9305331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease.
    Hauser RA; Schapira AH; Barone P; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W;
    Eur J Neurol; 2014 May; 21(5):736-43. PubMed ID: 24834511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate.
    Drijgers RL; Verhey FR; Tissingh G; van Domburg PH; Aalten P; Leentjens AF
    J Neurol Sci; 2012 Sep; 320(1-2):121-6. PubMed ID: 22824349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pramipexole and Parkinson's disease, an update].
    Martínez-Corral M; Kulisevsky J
    Rev Neurol; 2008 Jan 1-15; 46(1):49-52. PubMed ID: 18214827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.